DexCom, Inc. $DXCM Shares Sold by Premier Fund Managers Ltd

Premier Fund Managers Ltd lessened its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 8.4% in the fourth quarter, Holdings Channel.com reports. The firm owned 198,786 shares of the medical device company’s stock after selling 18,300 shares during the period. Premier Fund Managers Ltd’s holdings in DexCom were worth $13,334,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the business. Trust Co. of Vermont grew its stake in DexCom by 14.8% during the 4th quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock valued at $74,000 after purchasing an additional 145 shares in the last quarter. CVA Family Office LLC grew its stake in DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 147 shares in the last quarter. IFP Advisors Inc grew its stake in DexCom by 24.7% during the 3rd quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock valued at $61,000 after purchasing an additional 178 shares in the last quarter. Personal CFO Solutions LLC grew its stake in DexCom by 5.0% during the 3rd quarter. Personal CFO Solutions LLC now owns 3,864 shares of the medical device company’s stock valued at $260,000 after purchasing an additional 185 shares in the last quarter. Finally, Inspire Advisors LLC grew its stake in DexCom by 2.5% during the 3rd quarter. Inspire Advisors LLC now owns 7,926 shares of the medical device company’s stock valued at $533,000 after purchasing an additional 194 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Trading Up 1.5%

NASDAQ:DXCM opened at $60.36 on Thursday. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $89.98. The firm has a market capitalization of $23.29 billion, a P/E ratio of 25.79, a P/E/G ratio of 1.03 and a beta of 1.40. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. The business has a 50 day simple moving average of $65.34 and a 200 day simple moving average of $66.33.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The business had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same quarter in the previous year, the firm posted $0.32 EPS. The business’s revenue for the quarter was up 15.0% compared to the same quarter last year. Equities research analysts predict that DexCom, Inc. will post 2.55 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Wells Fargo & Company lowered their price objective on DexCom from $93.00 to $85.00 and set an “overweight” rating for the company in a research note on Friday, February 13th. Mizuho set a $75.00 price objective on DexCom in a research note on Friday, May 1st. Morgan Stanley reiterated an “overweight” rating on shares of DexCom in a research report on Monday, January 12th. TD Cowen decreased their target price on DexCom from $84.00 to $75.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Finally, Sanford C. Bernstein set a $77.00 target price on DexCom in a research report on Friday, May 1st. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $83.50.

Insiders Place Their Bets

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $63.04, for a total transaction of $107,168.00. Following the sale, the executive vice president owned 111,204 shares of the company’s stock, valued at $7,010,300.16. The trade was a 1.51% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.28% of the stock is owned by insiders.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.